Healthplus.ai, an Amsterdam-based digital health and artificial intelligence company, has announced a €2.3M funding round to accelerate development and geographic expansion of its AI-powered platform for surgical care management. Elevating Capital led the investment, with backing from LUMO Labs, ROM InWest, Pathena, and Leistone (Renza Family).
The startup's core offering, PERISCOPE, is an ISO- and CE-certified AI system designed to forecast complications following surgery, reduce infection rates, shorten patient recovery times, and lower institutional healthcare expenditures. The platform analyzes electronic health record data to assess infection likelihood for individual patients, enabling clinical teams to intervene sooner and make more informed discharge decisions.
Addressing a Global Surgical Challenge
Founded in 2017 by Bart Geerts and Bart Steverink, Healthplus.ai operates as a medical technology enterprise focused on minimizing surgical complications and facilitating complete recovery. The problem the company addresses is substantial: globally, approximately one in three surgical patients encounters a complication, impacting more than 70 million individuals annually. Meanwhile, roughly five billion people worldwide still lack access to safe and affordable surgical and anesthesia services. Post-operative infections represent the leading source of complications, yet they frequently go undetected for days after the procedure.
PERISCOPE integrates with existing hospital infrastructure, operates seamlessly within established clinical workflows, and adapts to each facility's patient demographics to ensure sustained accuracy and regulatory compliance. The system helps hospitals reduce complication-related expenses while bolstering surgical team capacity. Healthplus.ai currently serves hospitals in the Netherlands, Belgium, Denmark, and the United Kingdom, with expansion plans underway for Nordic nations and North America, including early-stage pilots in the United States.
Capital Allocation and Growth Strategy
The company intends to deploy the fresh capital toward strengthening its European and American footprint by obtaining FDA approval, enhancing system integrations, and establishing connections with major EHR vendors including Epic, Cerner, and ChipSoft. Additionally, Healthplus.ai plans to broaden its AI risk assessment models to encompass the entire perioperative journey and address multiple complication categories.
Dr Bart Geerts, CEO and founder of Healthplus.ai, stated: "With this late-seed investment, we're strengthening our ability to bring clinically validated, regulatory-approved AI into everyday hospital practice. Our focus remains on close collaboration with surgeons, clinicians, and hospital IT teams to ensure that predictive insights truly improve patient outcomes."
Roel Waals, Founding Partner of Elevating Capital, commented: "We see in this team strong execution capabilities, a scalable business model, and a clear contribution to the future of healthcare."
Investor Perspectives
Andy Lurling, founding partner of LUMO Labs and an early investor since 2022, remarked: "AI is critical to reform our healthcare system and to relief the increasing strain on nurses, doctors, and budgets, while upholding or even improving the high level of care we are used to. The adoption of MedTech AI requires not just two of the things Healthplus.ai does extremely well, that is, understanding the needs of the user and proving impact. It also requires two things that not all investors are too keen on: regulation and certification, processes that can be lengthy, unpredictable, and costly. This is why raising capital, even for the most successful MedTech AI startup, can be exceptionally challenging, especially in more risk adverse parts of the world, like here."
Antonio Murta, Co-Managing Partner and CEO of PATHENA, added: "The ability to accurately predict infections in hospitalised patients is critical both to better protect their lives and to manage the cost of—and risk of resistance to—antibiotic use in a hospital setting. We are very happy to join the supporting squad of Healthplus.ai."
Tim Heijink, General Manager at Leistone, noted: "Healthplus.ai demonstrates that true healthcare innovation is not only about increasing efficiency but also about improving patient outcomes. This aligns perfectly with Leistone B.V.'s investment strategy: supporting technology-driven ventures that create real impact. We believe Healthplus.ai is a driver of a smarter, safer, and future-proof healthcare system."
Sara Schaafsma, Investment Manager at ROM InWest, stated: "We are excited about our investment in the North Holland–based Healthplus.ai. With unprecedented accuracy, Healthplus.ai predicts postoperative infections, enabling faster patient recovery, more efficient workflows for specialists, and easing the burden on the healthcare system. We are proud that through this investment, we can contribute to a future-proof healthcare system."
Source: Silicon Canals
